eureKARE launches with $60 million to build and finance next generation biotech companies in Europe streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Learn more
The following content is provided by an advertiser or created on behalf of an advertiser. It is not written by the NutraIngredients-usa.com editorial team, nor does it necessarily reflect the opinions of NutraIngredients-usa.com.
LIPINOVA SPMs: a clinically proven immune-nutrition solution for the management of inflammation
17-May-2021
The lifestyle habits and decisions of societies today such as poor nutrition, alcohol and tobacco consumption, inadequate physical activity as well as pollution and stress, give rise to 75% of the chronic disease suffered today including cardiovascular disease (CVD), atherosclerosis, metabolic syndrome, cancer, osteoarticular health, and neurodegenerative diseases among others. These illnesses are caused or exacerbated by unresolved or uncontrolled inflammation and have a deficit of ‘Specialized Pro-resolving Mediators’ (SPMs), or an imbalance in the mediators of the inflammatory response. A familiar occurrence of uncontrolled infl
INVENTIVA: Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases
Revenues of €0.1m in Q1 2021
Decision by AbbVie to move into Phase IIb clinical development with cedirogant in psoriasis, following promising results in its Phase Ib clinical trial
Daix (France), May 12, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of March 31, 2021 and its revenues for the first quarter of 2021, and provided an update on its collaboration with AbbVie in auto-immune diseases.
Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Ac
It is estimated that 30 to 40 percent of adults in the United States have fatty liver disease, which is between one-third and one-half of all the people you know! Given how common fatty liver is, everyone needs to understand what it means, how to treat it, and what you can do if your doctor ever looks at your blood test and tells you that you have what s called Nonalcoholic Fatty Liver Disease, or NAFLD.
Fatty Liver is a condition where fat deposits build up in the liver, one of the most important organs in the body, responsible for filtering and clearing all the various foods and chemicals that enter your body. When your liver is healthy, you never really think about it, but when it gets clogged up with fat it can cause problems that have far-reaching health ramifications. Nonalcoholic Fatty Liver Disease is largely influenced by lifestyle choices and what you eat can play a big role in reversing it. That s good news since it means we can influence the amount of fat in our l